$35.13 -$0.52 (-1.5%)

01:18 PM EDT on 05/23/19

Fibrogen (NASDAQ:FGEN)

CAPS Rating: 4 out of 5

Current Price $35.13 Mkt Cap $3.1B
Open $35.04 P/E Ratio 0.00
Prev. Close $35.65 Div. (Yield) $0.00 (0.0%)
Daily Range $34.00 - $35.37 Volume 52,514
52-Wk Range $33.51 - $61.20 Avg. Daily Vol. 14

Caps

How do you think NASDAQ:FGEN will perform against the market?

Add Stock to CAPS Watchlist

All Players

49 Outperform
2 Underperform
 

All-Star Players

20 Outperform
1 Underperform
 

Wall Street

2 Outperform
0 Underperform
 

Top NASDAQ:FGEN Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

usubanas (99.43)
Submitted May 19, 2015

One of the best pipelines I've seen for a $1.2 billion biotech. Very long term though as important catalysts are in 2016.

zzlangerhans (99.81)
Submitted November 30, 2015

I think Fibrogen is vulnerable to a decline especially if the biopharma sector starts taking on water again. The company has a lofty 1.8B valuation despite being behind low-valued competitor Akebia in development of their HIF inhibitor. CTGF antibody… More

NASDAQ:FGEN VS S&P 500 (SPY)

NASDAQ:FGEN Summary

Fools bullish on NASDAQ:FGEN are also bullish on:

Fools bearish on NASDAQ:FGEN are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about FGEN.

Recs

0
Member Avatar mdriver78 (67.98) Submitted: 5/15/2019 3:40:06 PM : Outperform Start Price: $36.85 NASDAQ:FGEN Score: -3.47

The source of FGEN's recent problem is confusion over the company’s recently released Phase 3 trial results for roxadustat, a drug intended for use in patients with chronic kidney disease who are on dialysis and have anemia.

A goal for the company in this trial was to show that roxadustat wasn’t inferior to an existing drug used to manage anemia in these patients, on a risk measure called MACE (major adverse cardiac events).

But the language used by FibroGen in its press release confused investors as to the drug’s potential.

Investors are often confused by clinical data, and sometimes when they read positive things in a negative way it can create a buying opportunity.

Recs

0
Member Avatar Bigsef77 (68.13) Submitted: 9/14/2018 11:08:48 AM : Outperform Start Price: $43.65 NASDAQ:FGEN Score: -24.48

FibroGen Receives Fast Track Designation From the U.S. FDA for Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis
GlobeNewswire•September 12, 2018
SAN FRANCISCO, Sept. 12, 2018 (GLOBE NEWSWIRE) -- FibroGen, Inc. (FGEN), a biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the company’s anti-CTGF antibody, pamrevlumab, for the treatment of patients with idiopathic pulmonary fibrosis (IPF). This follows review of the Phase 2 clinical data evaluating pamrevlumab in a placebo-controlled trial and represents recognition by the FDA that pamrevlumab has the potential to address an unmet medical need for this disease.

“This Fast Track designation reflects recognition of the great need for a new therapeutic to help patients diagnosed with IPF to reduce the burden and progression of this debilitating disease and another positive step in developing pamrevlumab for the treatment of IPF,” said Elias Kouchakji, M.D., Senior Vice President, Clinical Development and Drug Safety. “We look forward to advancing pamrevlumab into Phase 3 studies early next year.”

Recs

0
Member Avatar CMFBLSH (86.74) Submitted: 10/24/2017 5:51:55 PM : Outperform Start Price: $58.15 NASDAQ:FGEN Score: -50.68

China significantly under-appreciated. Expect a Chinese FGEN-sub IPO after approval in China. AZN and Astellas are fronting development costs. FG-3019 has good potential in pancreatic cancer.

Leaderboard

Find the members with the highest scoring picks in FGEN.

Score Leader

ColinBalsbaugh

ColinBalsbaugh (33.80) Score: +102.41

The Score Leader is the player with the highest score across all their picks in FGEN.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
monkeyboy2006 < 20 6/21/2016 7/11/2016 Outperform 5Y $15.30 +129.15% +34.92% +94.23 0 Comment
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. bodostar 70.02 10/31/2016 Outperform 5Y $16.95 +106.84% +32.06% +74.79 0 Comment
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. ababrmon 90.50 5/20/2015 Outperform 1Y $17.36 +101.96% +32.26% +69.70 0 Comment
gunda7907 < 20 5/20/2015 Outperform 5Y $18.53 +89.21% +31.80% +57.40 0 Comment
jeepdrew222 65.09 9/8/2016 Outperform 5Y $19.29 +81.75% +28.70% +53.05 0 Comment
King2061x 37.64 8/8/2017 Underperform 5Y $50.50 -30.57% +13.42% +43.99 0 Comment
dollarsandcents1 < 20 2/16/2016 Outperform 5Y $18.20 +92.64% +49.05% +43.59 0 Comment
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. usubanas 99.43 5/19/2015 Outperform 5Y $20.00 +75.30% +31.95% +43.35 4 Comments
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. efarev 98.83 6/9/2015 Outperform 5Y $20.65 +69.78% +34.98% +34.80 0 Comment
DoubleBagel 34.30 2/1/2017 Outperform 5Y $22.55 +55.48% +23.74% +31.74 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Player Name Player
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score End Date Commentary
TrackCreditSuiss 89.41 2/11/2016 Outperform NS $16.09 +117.93% +54.31% +63.63 0 Comment
TrackStifel 88.82 12/9/2014 Outperform NS $26.60 +31.80% +37.67% -5.87 0 Comment

Advertisement